GVHD Alliance to Honor Steven Pavletic With the Inaugural Lukas D. Wartman GVHD Achievement Award ORLANDO, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- In recognition of the first-ever GVHD (graft-versus-host disease) Day, the American Society for Transplantation and Cellular Therapy (ASTCT), a...

ElsaLys Biotech annonce l'acceptation par la FDA du dépôt de sa demande de mise sur le marché pour LEUKOTAC® (inolimomab) pour le traitement de la maladie du greffon contre l'hôte chez l’adulte ElsaLys Biotech annonce  l'acceptation  par  la  FDA du  dépôt de  sa  demande de mise sur le marché pour LEUKOTAC® (inolimomab) pour le traitement de la maladie du greffon contre l'hôte chez l’adulte...

ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients        ·The Biologics License...

LEUKOTAC ® (inolimomab) is available again in France, following the granting of cohort ATU for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV LEUKOTAC ® (inolimomab) is available again in France, following the granting of cohort ATU for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with...